Upgrade to SI Premium - Free Trial

Jaguar Health (JAGX)

2.46 -0.23 (8.55%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/19/26)

Latest Headlines

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases June 12, 2026 9:01 AM - StreetInsider Form 8-K Jaguar Health, Inc. For: Jun 08 June 11, 2026 9:01 AM - SEC Filing Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream June 9, 2026 7:00 AM - Globe NewsWire Form 8-K Jaguar Health, Inc. For: Jun 08 June 8, 2026 4:41 PM - SEC Filing Jaguar Health reports stockholder approval of all annual meeting proposals June 8, 2026 4:16 PM - StreetInsider Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders June 8, 2026 4:15 PM - StreetInsider Form 8-K Jaguar Health, Inc. For: Jun 01 June 2, 2026 4:10 PM - SEC Filing Form DEFA14A Jaguar Health, Inc. May 29, 2026 5:24 PM - SEC Filing Jaguar Health advances crofelemer development for rare gastrointestinal disorders May 28, 2026 10:02 AM - StreetInsider Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders May 28, 2026 10:00 AM - StreetInsider Form 8-K Jaguar Health, Inc. For: May 26 May 27, 2026 9:10 AM - SEC Filing Jaguar Health regains compliance with NASDAQ bid price rule May 27, 2026 9:01 AM - StreetInsider Jaguar Health Compliant with Nasdaq Bid Price Rule May 27, 2026 9:01 AM - StreetInsider Form 8-K Jaguar Health, Inc. For: May 21 May 22, 2026 5:23 PM - SEC Filing Jaguar Health (JAGX) Misses Q1 EPS by 1360c May 21, 2026 11:10 AM - StreetInsider Jaguar Health Reports First Quarter 2026 Financials May 20, 2026 4:40 PM - StreetInsider Form 8-K Jaguar Health, Inc. For: May 20 May 20, 2026 4:36 PM - SEC Filing Form 10-Q Jaguar Health, Inc. For: Mar 31 May 20, 2026 4:07 PM - SEC Filing Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference May 20, 2026 9:04 AM - StreetInsider Form 8-K Jaguar Health, Inc. For: May 19 May 19, 2026 5:07 PM - SEC Filing Jaguar Health advances MVID drug trial to extension phase May 19, 2026 9:04 AM - StreetInsider Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) May 19, 2026 9:02 AM - StreetInsider Form NT 10-Q Jaguar Health, Inc. For: Mar 31 May 18, 2026 3:06 PM - SEC Filing Jaguar Health regains NASDAQ compliance, gets extension to meet bid price rule May 8, 2026 9:01 AM - StreetInsider Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule May 8, 2026 9:01 AM - StreetInsider Form 8-K Jaguar Health, Inc. For: May 06 May 7, 2026 2:59 PM - SEC Filing Jaguar Health discusses FDA breakthrough therapy designation for rare disease treatment May 6, 2026 9:01 AM - StreetInsider Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) May 6, 2026 9:00 AM - StreetInsider Form DEFA14A Jaguar Health, Inc. May 6, 2026 8:00 AM - SEC Filing Form 8-K Jaguar Health, Inc. For: May 04 May 4, 2026 5:10 PM - SEC Filing Jaguar Health launches Neonorm Dog for canine digestive health May 4, 2026 8:31 AM - StreetInsider Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health May 4, 2026 8:30 AM - StreetInsider Form 8-K Jaguar Health, Inc. For: May 01 May 4, 2026 8:00 AM - SEC Filing Form DEF 14A Jaguar Health, Inc. For: May 22 April 30, 2026 10:13 AM - SEC Filing Form ARS Jaguar Health, Inc. For: Dec 31 April 30, 2026 6:06 AM - SEC Filing Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs April 29, 2026 8:36 AM - StreetInsider Form 8-K Jaguar Health, Inc. For: Apr 24 April 27, 2026 9:10 AM - SEC Filing Jaguar Health gets nasdaq extension, plans 1-for-35 reverse stock split April 27, 2026 9:08 AM - StreetInsider Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split April 27, 2026 9:07 AM - StreetInsider Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterolog April 24, 2026 8:35 AM - StreetInsider Form PRE 14A Jaguar Health, Inc. For: May 22 April 21, 2026 8:22 AM - SEC Filing Form 8-K Jaguar Health, Inc. For: Apr 20 April 21, 2026 7:35 AM - SEC Filing Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders April 20, 2026 4:15 PM - StreetInsider Jaguar Health plans AI integration for rare disease drug development April 13, 2026 8:32 AM - StreetInsider Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs April 13, 2026 8:31 AM - StreetInsider Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates April 9, 2026 8:17 PM - StreetInsider Form 8-K Jaguar Health, Inc. For: Apr 07 April 9, 2026 5:05 PM - SEC Filing Jaguar Health completes dog diarrhea drug effectiveness trial April 8, 2026 8:32 AM - StreetInsider Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs April 8, 2026 8:30 AM - StreetInsider Form S-8 Jaguar Health, Inc. April 7, 2026 5:11 PM - SEC Filing Form 8-K Jaguar Health, Inc. For: Apr 07 April 7, 2026 12:54 PM - SEC Filing Form 10-K Jaguar Health, Inc. For: Dec 31 April 7, 2026 12:40 PM - SEC Filing Jaguar Health Reports 2025 Financials April 7, 2026 8:41 AM - StreetInsider Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress April 2, 2026 9:00 AM - StreetInsider Form NT 10-K Jaguar Health, Inc. For: Dec 31 April 1, 2026 4:19 PM - SEC Filing Form DEF 14A Jaguar Health, Inc. For: Apr 20 March 24, 2026 5:06 PM - SEC Filing Jaguar Health receives FDA support for MVID trial extension phase March 18, 2026 9:01 AM - StreetInsider FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) March 18, 2026 9:01 AM - StreetInsider Full Article List